First AD

Second AD

objectives, clinical endpoints, and safety profile of the Phase 2 ZUMA-3 clinical trial

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Expert Insights into the Efficacy and Safety of Brexucabtagene Autoleucel CART19 Cell Therapy in Adults with Advanced Acute Lymphoblastic Leukemia

Insights

Dr. Bijal and colleagues discuss the objectives, clinical outcomes, and safety profile of the Phase 2 ZUMA 3 clinical trial, which evaluated treatment of adult patients with relapsed or refractory, B-precursor, acute lymphoblastic leukemia with the anti-CD-19/anti-CD20 bispecific CAR-T cell therapy, KTE-X19 (brexucabtagene autoleucel).

Objectives, Clinical Endpoints, and Safety Profile of the Phase 2 ZUMA-3 Clinical Trial

Faculty Introductions

Objectives of the 2023 ASH Insights Program on CAR-T Cell Therapy for Adult B Cell ALL

Overview of the Current State of CART19 Therapy for Adult Patients With R/R ALL

Progression-Free Survival, Overall Survival, and the Prognostic Significance of Negative Minimal Residual Disease

Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion

Outcomes of the Retrospective, Multicenter ROCCA Analysis (Real-World Outcomes Collaborative of CAR-T in Adult ALL)

Influences on Treatment Response and Survival in Recipients of Brexucabtagene Autoleucel Therapy

Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL

Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia